LakeShore Biopharma Files 6-K Report
Ticker: LSBWF · Form: 6-K · Filed: Dec 19, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Dec 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, regulatory-filing
TL;DR
LakeShore Biopharma (fka YishengBio) filed a 6-K on Dec 19, 2024. Standard update.
AI Summary
LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on December 19, 2024. The company, incorporated in E9 and headquartered in Beijing, PRC, is a pharmaceutical preparations company. This filing is for the month of December 2024 and is being made under the 1934 Securities Exchange Act.
Why It Matters
This filing provides an update on the company's activities and regulatory compliance for the period. Investors and stakeholders can review it for the latest information on the company's operations and any material developments.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain new material financial or operational information that would typically indicate a change in risk.
Key Numbers
- 001-41598 — Commission File Number (Identifies the specific SEC filing series for the company.)
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- YS Biopharma Co., Ltd. (company) — Former Company Name
- YishengBio Co., Ltd (company) — Former Company Name
- 001-41598 (dollar_amount) — Commission file number
- 20241219 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
When was LakeShore Biopharma Co., Ltd. formerly known as YS Biopharma Co., Ltd.?
The date of name change from YS Biopharma Co., Ltd. to LakeShore Biopharma Co., Ltd. was March 10, 2023.
What is the SIC code for LakeShore Biopharma Co., Ltd.?
The Standard Industrial Classification (SIC) code for LakeShore Biopharma Co., Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Where is LakeShore Biopharma Co., Ltd. headquartered?
The company's principal executive offices are located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
What is the fiscal year end for LakeShore Biopharma Co., Ltd.?
The fiscal year end for LakeShore Biopharma Co., Ltd. is March 31.
Filing Stats: 251 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-12-19 09:28:10
Filing Documents
- ea0225316-6k_lakeshore.htm (6-K) — 12KB
- ea022531601ex99-1_lakeshore.htm (EX-99.1) — 119KB
- 0001213900-24-110338.txt ( ) — 132KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F INCORPORATION BY REFERENCE This current report on Form 6-K, including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into LakeShore Biopharma Co., Ltd’s registration statements on Form S-8 (File No. 333-279544 and File No. 333-273165 ) and to be a part thereof from the date on which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. 1 EXHIBITS Exhibit No. Description 99.1 Press Release – LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: December 19, 2024 3